IMPACT OF FACTOR VIII GENE (F8) MUTATION ON IMMUNE TOLERANCE INDUCTION (ITI) OUTCOMES IN HAEMOPHILIA A PATIENTS WITH INHIBITORS IN THE OBSITI STUDY

被引：0
|
作者：
Pavlova, A. [1 ]
Escuriola-Ettingshausen, C. [2 ]
Oldenburg, J. [1 ]
机构：
[1] Univ Clin Bonn, Inst Expt Haematol & Transfus Med, Bonn, Germany
[2] HZRM Hamophilie Zentrum Rhein Main GmbH, Morfelden Walldorf, Germany
来源：
HAEMOPHILIA | 2020年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P055
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [41] Factor VIII inhibitor bypass activity (Feiba) for prophylaxis during immune tolerance induction (ITI) in patients with high-responding inhibitors.
    Kreutz, W
    Escuriola-Ettinghausen, C
    Mentzer, D
    Martinez, I
    Becker, S
    Stoll, H
    Heller, C
    BLOOD, 2000, 96 (11) : 266A - 266A
  • [42] Economic Impact of Immune Tolerance Induction (ITI) with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Compared to Conventional Recombinant Factor VIII (rFVIII)
    Li, Nanxin
    Wilson, Koo
    Botteman, Marc
    Nicoloso, Daniel
    Krishnan, Sangeeta
    Su, Jun
    BLOOD, 2018, 132
  • [43] Immune tolerance induction (ITI) according to the Bonn protocol in haemophilia A patients with inhibitors using a plasma-derived VWF-containing factor VIII concentrate: two paediatric case reports
    Lohse, J.
    Gehrisch, S.
    Escuriola-Ettingshausen, C.
    Kreuz, W.
    Knoefler, R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 1073 - 1074
  • [44] Immune tolerance outcome and economics retrospective registry (iter-study) of patients with haemophilia A (ha) and factor VIII inhibitors
    Rocino, A.
    Gringeri, A.
    Lambert, T.
    Klamroth, R.
    Lopez-Fernandez, F. M.
    Diniz, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 520 - 520
  • [45] Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors
    Rocino, Angiola
    Santagostino, Elena
    Mancuso, Maria Elisa
    Mannucci, Pier Mannuccio
    HAEMATOLOGICA, 2006, 91 (04) : 558 - 561
  • [46] Experience with a third generation recombinant factor VIII concentrate (Advate®) for immune tolerance induction in patients with haemophilia A
    Valentino, L. A.
    Recht, M.
    Dipaola, J.
    Shapiro, A. D.
    Pipe, S. W.
    Ewing, N.
    Urgo, J.
    Bullock, T.
    Simmons, M.
    Deguzman, C.
    HAEMOPHILIA, 2009, 15 (03) : 718 - 726
  • [47] Update on the immune tolerance and economics retrospective registry (ITER) of patients with haemophilia A (HA) and factor VIII inhibitors
    Gringeri, A.
    Rocino, A.
    Astermark, J.
    Diniz, M. J.
    Fijnvandraat, K.
    Klamroth, R.
    Lavigne-Lissalde, G.
    Lambert, T.
    Lopez-Fernandez, M. F.
    Morfini, M.
    Altisent, C.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 510 - 511
  • [48] Immune Tolerance Induction (ITI) With Factor IX and Combined Immunosuppressive Therapy in two Patients With Severe Haemophilia B, Longstanding Inhibitors and Previous Allergic Reactions
    Holstein, K.
    Voigtlaender, M.
    Dicke, C.
    Langer, F.
    HAEMOPHILIA, 2017, 23 : 93 - 93
  • [49] A retrospective study evaluating immune tolerance induction (ITI) with a plasma-derived factor VIII for patients with hemophilia A and high titer inhibitor
    Escobar, M.
    Sahffer, L.
    Holguin, M.
    McCavit, T.
    Amega, N.
    HAEMOPHILIA, 2019, 25 : 27 - 28
  • [50] Predictors of the outcome of immune tolerance induction in patients with haemophilia A and inhibitors: The Brazilian Immune Tolerance (BrazIT) Study protocol
    Camelo, Ricardo Mesquita
    Chaves, Daniel Goncalves
    Zuccherato, Luciana Werneck
    Rezende, Suely Meireles
    PLOS ONE, 2021, 16 (08):
12345